Evidentially, a major driver of neovascularization in PDR is the vascular endothelial growth factor (VEGF) targeted effectively in routine treatment of diabetic macular edema (DME) and PDR by the application of anti-VEGF antibodies or decoy antibody receptors [5]. The gene discussed is VEGFA; the disease is diabetic macular edema.